Seres Therapeutics, Inc. (MCRB)
| Previous close | 6.22 |
| Open | 6.21 |
| Bid | 6.26 x 900 |
| Ask | 6.27 x 800 |
| Day's range | 6.14 - 6.32 |
| 52-week range | 5.41 - 38.50 |
| Volume | 309,322 |
| Avg. volume | 1,753,436 |
| Market cap | 575.076M |
| Beta (5Y monthly) | 3.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.48 |
| Earnings date | 08 Nov 2021 - 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.57 |
- Business Wire
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
CAMBRIDGE, Mass., October 26, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). New data from an exploratory analysis demonstrate SER-109 reduced the risk of rCDI compared to placebo in patients with risk factors for recurrence, including those taking acid-reducing medications
- PR Newswire
Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.
- Business Wire
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
CAMBRIDGE, Mass., October 02, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced late-breaking data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI). SER-109 was associated with significantly greater reduction of antimicrobial resistance genes (ARGs) compared to placebo, with the reduction observed both rapidly (by Week 1) and sustained through W
